Pulmatrix Reports Q2 2018 Results
Pulmatrix, Inc. (PULM)
Last pulmatrix, inc. earnings: 8/5 09:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.pulmatrix.com
Company Research
Source: PR Newswire
LEXINGTON, Mass., Aug. 3, 2018 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) today reports its second quarter results. "We are pleased with the preliminary results of the three-part Phase 1/1b clinical trial of Pulmazole. The data supports the potential of Pulmazole to improve the lives of patients with ABPA and we look forward to initiating a Phase 2 study of Pulmazole in patients with asthma and ABPA, currently planned to start in the fourth quarter of this year," said Robert W. Clarke, Ph.D., chief executive officer of Pulmatrix. FinancialsAs of June 30, 2018, Pulmatrix had $8.3 million in cash and cash equivalents, compared to $3.6 million as of December 31, 2017. Research and development expenses for the second quarter of 2018 were $4.0 million, compared to $3.4 million for the same period last year. The increase was primarily due to increases in clinical development costs and external service costs on the Pulmazole program. General and administrative
Show less
Read more
Impact Snapshot
Event Time:
PULM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PULM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PULM alerts
High impacting Pulmatrix, Inc. news events
Weekly update
A roundup of the hottest topics
PULM
News
- Pulmatrix, Inc. (NASDAQ: PULM) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- 14-alpha Demethylase Inhibitors Drug Landscape Research Report 2024: Comprehensive Insights on 12+ Companies and 12+ Pipeline Drugs [Yahoo! Finance]Yahoo! Finance
- Pulmatrix, Inc. (NASDAQ: PULM) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Pulmatrix, Inc. (NASDAQ: PULM) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
PULM
Sec Filings
- 3/28/24 - Form 424B3
- 3/28/24 - Form 10-K
- 3/28/24 - Form 8-K
- PULM's page on the SEC website